🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

As vaccines typically require years to produce, let's recognize the scientists who are racing to produce a safe & effective #coronavirus #vaccine by next year. It’s difficult to see how pharma can go back to taking years to generate vaccines & other drugs. nyti.ms/36CXRUp

Join Andrew Bradbury for the Antibody Engineering Virtual Conference, where he'll discuss #Antibody Selection & Screening in Early Discovery, 12/16 @ 12:15 EST, plus host an on-demand session on Drug-like #Antibodies Straight from Selections. bit.ly/3q0r2sr #AntibodyEng

Comprised of five sub-libraries, our Generation 3 Library Platform has quality built in by design - offering developability, extremely high diversity, and the exclusion of sequence liabilities. bit.ly/2GkOGxu #antibodies #therapeutics #biotech

The The New York Times shares a #coronavirus drug & treatment tracker, analyzing the most-talked-about treatments for the virus in terms of the evidence available, including the use of #monoclonalantibodies, #interferons & #convalescentplasma as treatments. nyti.ms/3n794Tg #COVID19

Great insights shared from Founder & CSO Andrew Bradbury during the recent Antibody Engineering Conference, where he & other industry leaders discussed “Antibody Selection & Screening in Early Discovery.” Full presentation replay available here: specifica.bio/webinars/ #AntibodyEng

Our goal in developing an #Antibody Discovery campaign is to generate as many different target-specific #antibodies as possible, w/the final product either a panel of antibodies in any format, or list of different antibody clonotype sequences. bit.ly/33LBRor #biotech

Highlighting a great article from the past year. In this nature piece by Vivien Marx🐘📬⛅️, co-founder & CSO Andrew Bradbury shared insights on the benefits of recombinant #antibodies & naive antibody libraries. #antibody #biotech #biotechnology ow.ly/j4Za50CVxst

A final look back on 2020... This nature article, co-authored by CSO Andrew Bradbury reviewed in vitro methods to generate recombinant animal-free #antibody alternatives within the metaphor of an “antibody iceberg.” #antibodies #biotech ow.ly/xwGK50CVxIZ

Upcoming free webinar. Registration is open. Specifica Andrew Bradbury webinars-antibodysociety.org/store/seminar/…

Via NPR: MDs encouraged by the use of #monoclonalantibodies as a #COVID19 treatment. Though there are logistical challenges, #healthcare professionals report success in deployment & results, emphasizing the value of #antibodies as therapeutics. #biotech ow.ly/SLJb50D5JJb

A study in NEJM of 12,500+ healthcare workers analyzed the extent to which those previously infected with #SARSCoV2 are protected from reinfection. Results: presence of anti-spike #antibodies was associated w/reduced risk in the ensuing 6 months. #biotech ow.ly/eBPu50D5KyQ

We believe there is tremendous value to fishing in your own #antibody “pond” when selecting therapeutic leads. That’s why we offer partners exclusive libraries, created from unique donor sets not used for any other library. #antibodies #biotech ow.ly/NfLE50D5Keg

Join CSO Andrew Bradbury & Head of Bioinformatics M Frank Erasmus for The Antibody Society’s webinar: #Antibody Discovery in the Cloud: Using #NGS to Expand the Universe of Selectable #Antibodies. We'll examine the use of NGS to build our libraries. #biotech ow.ly/AonL50D9LMx

Join CSO Andrew Bradbury & Head of Bioinformatics M Frank Erasmus for the webinar Using #NGS to Expand the Universe of Selectable #Antibodies." They'll examine the Gen 3 platform, which enables identification of leads with broad epitope coverage. #biotech ow.ly/drTO50DczGT

.News Medical shared new research on #SARSCoV2, showing how closely the #antibodies formed in exposed humans resemble germline #antibody molecules which could lead to the development of novel antibody #therapeutics to counter the #pandemic. #covid19 ow.ly/DH6D50Dbzo6

Why choose the Specifica platform? With visionary #antibody technologies, we're focused on empowering you to generate antibody drugs against any target, to create cures for any disease with our exceptional, exclusive #AntibodyLibraries. #antibodies ow.ly/8ZRn50DbA1Y

Via Genetic Engineering & Biotechnology News, a look at #monoclonalantibodies, their biological complexities & the innovative new approaches for production and use, as the global therapeutic monoclonal #antibody market is expected to generate revenue of $300B by 2025. #biotech #antibodies ow.ly/g4Ew50Dk7Z3

Our mission is to empower companies with visionary #antibody technologies. By using Next Generation Sequencing (#NGS) throughout construction & output analyses, we can directly measure the diversity of each exclusive library we build. #biotech ow.ly/FACp50Dk9jQ

Interested in learning about our Gen 3 Library Platform? Our webinar “High Quality #Antibodies Straight From Selections” shares how the platform offers developability, extremely high diversity & the exclusion of sequence liabilities. #biotech ow.ly/Mcr150D5L7n